Ionis Pharmaceuticals (IONS) said Monday that a study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease met its primary endpoint, as well as all key secondary endpoints.
Results showed a "statistically significant" placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80-milligram and 50 mg monthly doses, respectively, the company said.
Olezarsen also showed a favorable safety and tolerability profile, according to Ionis.
The company expects data from the pivotal phase 3 CORE and CORE2 studies assessing olezarsen to treat severe hypertriglyceridemia in Q3.
Triglycerides are a kind of fat the body uses as a source of energy.
Ionis shares were up 1% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。